

FORM OF FINAL TERMS

FINAL TERMS DATED 03.01.2025 / 19.12.2025

10C PCC

(incorporated in Jersey)

Acting in respect of 10C Cell 13 PC

Issue of

OPTIROI AMC CHF (the Securities)

ISIN CH1393579805

pursuant to the Issuer's

Structured Products and Certificates Program

This document constitutes the Final Terms of the Securities of the Product described herein.

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions of the Securities (the **Terms and Conditions**) issued by 10C PCC on behalf of 10C Cell 13 PC (the **Issuer**) set forth in the Base Prospectus dated 19.12.2025¹ (the **Base Prospectus**). This document constitutes the Final Terms of the Securities described herein and must be read in conjunction with the Base Prospectus (and any supplement thereto). Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus (together with any supplement thereto) and these Final Terms are available for viewing at the registered office of the Paying Agent and on the website www.bankfrick.li.

The Base Prospectus, together with the Final Terms, constitutes the prospectus with respect to the Securities described herein for the purposes of the Regulation (EC) 2017/1129 (the "Prospectus Regulation").

The JFSC has granted consent to the Issuer under Article 4 of the Control of Borrowing (Jersey) Order 1958.

Issue Date	13.01.2025
Issue Size	Up to 1'000'000 products (with reopening clause)
Security Type	Debt instrument (Products)
Initial Issue Price	CHF 1'000 per product
Underlying	The Underlying is a basket representing an actively managed portfolio of assets and cash, which together shall be referred to as the "Basket". The basket is selected and managed by the Investment Manager in accordance with this termsheet, in particular the "Investment Strategy" referred to here below. The precise composition and weighting of the Basket can vary based on market conditions, the stipulated investment strategy, and trading decisions based on different approaches of algorithms.
Basket	Applicable
Index	Not Applicable

¹ Prolongation of the initial Base Prospectus dated 20.12.2023.

Base Currency	CHF
Settlement Currency	CHF
Reference Source(s) for Underlying prices	The Reference Source(s) for the price of the Underlying are: Market/Exchanges Prices
Hedging Arrangements	Not Applicable
Subscriptions	On behalf of its client, the investor's depositary bank submits a binding offer to the Paying Agent in writing, by e-mail or by telephone for the purchase of the notes with the desired nominal amount. The bond is acquired by acceptance of the offer by the issuer, represented by the Paying Agent. The issuer reserves the right not to accept a subscription offer. Subscription orders can be placed on bank working days (Balzers, Liechtenstein) during normal opening hours by the depositary bank between 08:00 and 17:00 (CET) via the paying agent as follows: E-mail: trading@bankfrick.li Fax: +423 388 21 22 Telephone: +423 388 21 25 The order confirmation is sent by the paying agent to the custodian bank placing the order by telephone or e-mail. The transaction can be settled using the "delivery against payment" (DVP) procedure.
Redemption Amount	Paying Agent & Calculation Agent: Bank Frick has been appointed as both the Paying Agent and Calculation Agent for the Products. In these capacities, Bank Frick will be responsible for payment-related matters and for the calculation of the Net Asset Value (NAV) of the Products. Net Asset Value (NAV) Calculation: The NAV represents the per-note value of the assets within the actively managed certificate. Bank Frick, as the Calculation Agent, will determine the NAV on a weekly basis in accordance with recognized and standard industry valuation methodologies and practices. Redemption Amount Calculation: Investors wishing to redeem their Products may do so at the NAV price determined by the Calculation Agent. The Redemption Amount is calculated as follows: $\text{NAV} = (\text{Total Assets} - \text{Total Fees}) \div \text{Total Outstanding Products}$ Where: Total Assets represent the aggregate value of all assets held within the basket. Total Fees encompass all applicable fees and charges associated with the management, operation, and administration of the product. Total Outstanding Products refers to the number of products that are currently issued and not redeemed. The Redemption Amount per note will be the NAV as calculated above. Investors will receive this amount for each note they wish to redeem, subject to any additional fees or charges as outlined elsewhere in this document. Additional Fees: The Redemption Amount may also be subject to additional fees related to the transfer of fiat assets. Investors should consult the fee schedule or inquire directly to get a comprehensive understanding of any potential costs or charges associated with the redemption process.

	Redemption Process: Investors wishing to redeem their Products should initiate the redemption process with the Trading Desk of Bank Frick AG (trading@bankfrick.li ; 00423 388 21 25). All redemptions will be processed in accordance with the terms and conditions stipulated in this document and any associated agreements.
Maturity Date	n/a, this is an open-ended Product The issuer has the right to redeem the certificate in part or in full at any time without giving reasons
Investor Redemption Date (put date)	Weekly, Friday 11:00 CET
Cut-off	Weekly, Friday 11:00 CET
Valuation Day	Every Monday
Valuation	The valuation is calculated on the valuation day using the closing prices of the day preceding the valuation day. If the valuation day is a banking holiday, the following day is taken as the valuation day. If the day preceding the valuation date is a banking holiday, the closing prices of the day preceding the banking holiday will be taken for calculation.
Cash Settlement	Yes (redemptions are settled within the next three working days following the valuation date, T + 2)
Amount of any expenses and taxes specifically charged to the subscriber or purchaser	Except as set out in the Base Prospectus ("Fees related to the Products"), all expenses related to the services provided by the service providers are included in the Investor Fee.
Yield / Yield Calculation Method	not applicable
Initial Valuation Date	20.01.2025
Valuation Frequency	weekly / Monday (with Friday closing prices)
Minimum Investment Amount	1 unit
Minimum Trading Lot	1 unit
Investor Fee	The Investor Fee is comprised as follows: • Management fee of 0% p.a. • Administration fee of CHF 0.00 p.a. (total on product level, not per investor) • Service fee of 0.30% p.a. Redemption fee up to 3% at discretion of IM Performance fee is calculated as follows: 33% with high-water mark (HWM). The performance fee is accrued weekly (HWM adjusted) and effectively paid out quarterly. Fees related to the Products will be collected in CHF. Fees relating to trading and custody are charged directly to the Basket.
Distribution Fee	Up to 3% at discretion of IM
Other Fees	Not Applicable
Specific Product Risks	Furthermore, investors should consider:

Regulatory Risks:

Legal, tax and regulatory changes could occur during the term of the Company that may adversely affect the Company and the AMC. The regulatory environment for hedge AMCs is evolving, and changes in the regulation of hedge AMCs may adversely affect the value of investments held by a AMC and the ability of a AMC to obtain the leverage it might otherwise obtain or to pursue its trading strategies. In addition, the securities and futures markets are subject to comprehensive statutes, regulations and margin requirements. Regulators and selfregulatory organisations and exchanges are authorised to take extraordinary actions in the event of market emergencies. The regulation of derivatives transactions and AMCs that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action. The effect of any future regulatory change on the Company and the AMC could be substantial and adverse. THE FOREGOING LIST OF RISK FACTORS DOES NOT PURPORT TO BE A COMPLETE EXPLANATION OF THE RISKS INVOLVED IN INVESTING IN THE AMC. POTENTIAL INVESTORS SHOULD READ THIS ENTIRE MEMORANDUM BEFORE DETERMINING WHETHER TO INVEST IN THE AMC AND CONSULT WITH THEIR OWN FINANCIAL AND TAX ADVISORS. POTENTIAL INVESTORS SHOULD ALSO BE AWARE THAT, IF THEY DECIDE TO PURCHASE SHARES, THEY WILL HAVE NO ROLE IN THE MANAGEMENT OF THE COMPANY AND WILL BE REQUIRED TO RELY ON THE EXPERTISE OF THE INVESTMENT MANAGER AND THE ADMINISTRATOR IN DEALING WITH THE FOREGOING (AND OTHER) RISKS ON A DAY-TO-DAY BASIS

Liquidity risk

Assets may also be acquired for the AMC that are not listed on a stock exchange or included in another organised market. The acquisition of such assets is associated with the risk that problems may arise in particular when reselling the assets to third parties.

In the case of securities of smaller companies (second-line stocks), there is a risk that the market may not be liquid at times. This may mean that securities cannot be traded at the desired time and/or in the desired quantity and/or at the desired price.

Market Risks:

Market risks. The success of a significant portion of the AMC investment programme will depend, to a great extent, upon correctly assessing the future course of the price movements of stocks, bonds, financial instruments and foreign currencies. There can be no assurance that the Investment Manager or investment AMC's manager will be able to predict accurately these price movements. Volatility. Investment techniques used may include the use of leverage and derivative instructions such as futures, options and short sales, which amplify the possibilities for both profits and losses and may add volatility to the AMC's performance. Investments in foreign and emerging markets. Investments in certain foreign securities may be subject to greater risks than investments in securities of issuers from member-States of the OECD due to a variety of factors including currency controls and currency exchange rate fluctuations, changes in governmental administration or economic or monetary policy or changed circumstances in dealings between nations. Dividends paid by foreign issuers may be subject to withholding and other foreign taxes that may decrease the net return on these investments. There may be less publicly available information about foreign issuers in certain countries and such issuers may not be subject to uniform accounting, auditing and financial reporting standards and requirements comparable to those of the AMC or most OECD issuers. In certain countries, securities of local issuers are less liquid and more volatile than securities of comparable issuers of more mature economies, and foreign brokerage commissions are generally higher than in more developed markets. Foreign securities markets may also be less liquid, more volatile and subject to lower levels of government supervision than those in the OECD. Investment in foreign countries could be affected by other factors not present in more developed countries, including expropriation, confiscatory taxation and potential difficulties in enforcing contractual obligations. These markets may be volatile and illiquid and the investments of the AMC in such markets may be considered speculative and subject to significant custody and clearance risks and delays in settlement. Investors should consult a professional advisor as to the suitability for them of an investment in the AMC investing in foreign and emerging markets. Subscriptions to Shares of the Company investing in such markets should be considered only by investors who are aware of, and able to bear, the risks related thereto and such investments should be made on a medium- to long-term basis.

Investment in currencies other than the Functional Currency specified in the Specific Terms. Portions of the AMC assets may be held or traded in currencies other than the Functional Currency specified in the Specific Terms and may therefore be subject to risks associated with investments in such currencies. In general, foreign exchange rates can be extremely volatile. Currency prices may be influenced by, among other factors: changing supply and demand for a particular currency; trade, fiscal and monetary policies of governments (including exchange control programmes, restrictions on local exchanges or markets and limitations on foreign investment in a country or on investment by residents of a country in other countries); political events; changes in balances of payments and trade; the Functional Currency's rate of inflation and the rate of inflation of the currencies other than the Functional Currency; international interest rates; international trade restrictions; and currency devaluations and revaluations. In addition, governments from time to time intervene, directly and by regulation, in the currency markets to influence prices directly. Variance in the degree of volatility of the market from the AMC expectations may produce significant losses to the AMC. Suspension of trading. Each securities exchange or commodities contract market typically has the right to suspend or limit trading in all securities or commodities which it lists. Such a suspension would render it impossible for the AMC and/or their investment AMCs to liquidate positions and, accordingly, expose the AMC to losses and delays in its ability to redeem Shares. Other investments. The AMC reserves the right to invest in equities, obligations, investment AMCs, or derivative structures based thereon which the Board and the Investment Manager at their sole discretion feel are consistent with the investment objectives and philosophy of the AMC. No assurance can be given that such investments will be successful. 76 Epidemics/Pandemics - The current coronavirus pandemic, and potential future viral epidemics or pandemics, could result in general economic decline and have an adverse impact on the AMC's investments, or the AMC's ability to source new investments or to realize its investments, in particular if such an epidemic persists for an extended period of time or continues to spread globally

Trading Risk:


All investments carry the risk of capital loss. The nature of the assets purchased and traded by the AMC and the investment techniques employed may increase this risk. Although the Investment Manager will strive to manage the AMC effectively, there can be no assurance that it will achieve its performance objectives or avoid losses. Many unforeseen events, including government actions and political developments, may cause market fluctuations. The Investment Manager may use strategies involving futures, options, derivatives, and foreign exchange (FOREX), which present unique risks. For example, if interest or exchange rates or security prices move unexpectedly, the AMC may not achieve the desired benefits or may incur losses. The correlation between price movements of securities and those hedged is often imperfect, resulting in unanticipated losses. Forward contracts, swaps, and other over-the-counter transactions carry credit risk, as they are not guaranteed by exchanges. Political or monetary policies may hinder the enforcement of contracts in foreign jurisdictions if a principal refuses to perform. Currently, there is no regulatory framework for the foreign currency forward market, except for general banking regulations. While the U.S. imposes no restrictions on currency movements, this could change, impacting market dynamics. When investing in derivatives, the AMC may need to segregate cash or high-quality assets to cover positions, potentially diminishing returns due to opportunity costs. Forward contracts and options are unregulated and traded privately, leading to potential illiquidity and market disruptions. Counterparty failures may occur, posing risks of significant losses for the AMC. Derivatives: The AMC may utilize both exchange-traded and OTC derivatives, including futures, forwards, swaps, options, and contracts for differences. These instruments can be highly volatile and expose investors to significant risk. The low initial margin requirements allow for high leverage, meaning even small price movements can lead to large profits or losses, potentially exceeding the margin deposited. Daily limits on price fluctuations may hinder prompt liquidation of positions, leading to greater losses.

	When used for hedging, there may be imperfect correlations with the underlying investments. OTC contracts carry additional risks as they lack an exchange market for closing positions, making it difficult to liquidate or assess their value. Contractual asymmetries can further increase risk, such as break clauses allowing counterparties to terminate transactions based on changes in Net Asset Value. The AMC may also sell covered and uncovered options on securities, with uncovered options posing the risk of unlimited losses. Risks of an AMC-of-AMCs: Investment in an AMC-of-AMCs carries specific risks. The Company may diversify by selecting multiple independent portfolio managers, which aims to offset losses and capitalize on profitable movements. However, this strategy does not guarantee net profits, as competing positions among managers or substantial positions in similar markets can hinder desired diversification. The Investment Manager selects portfolio managers based on their performance and strategy, but may not always receive complete information, as some data may be proprietary. This lack of access complicates selection and evaluation. Allocating assets to new portfolio managers with limited track records poses additional risks due to insufficient information on their risk/reward profiles. When shares are redeemed, the value reflects the Company's investments, but some portfolio managers may not allow immediate redemptions, resulting in the Company bearing the risk of fluctuations in value until it can withdraw capital. The Company relies on third-party managers for broker, banker, and counterparty choices, incurring indirect expenses related to their operations. Portfolio managers may charge fixed fees and incentive fees, which reduce the Company's profits. Despite selecting managers with high integrity, the Company cannot control their daily operations, leading to potential misconduct. Additionally, the Company's structure may restrict asset allocation and risk control due to the limited liquidity and transparency of portfolio managers. Capital withdrawal could be delayed despite significant losses. Portfolio managers may receive compensation based on account appreciation, potentially incentivizing riskier investments, and the Company may owe fees to managers even in loss years. Finally, the AMC-of-AMCs structure may result in higher costs for shareholders compared to direct investments in portfolio managers, as both the portfolio managers and the Investment Manager charge fees. Counterparty and Settlement Risk: The AMC faces counterparty and settlement risks, as it relies on the ability of counterparties, including portfolio managers, brokers, and custodians, to fulfill their obligations. If a counterparty fails to do so due to insolvency or other issues, the AMC may incur losses and is exposed to credit risk. Additionally, any default by a counterparty or on settlement could significantly impact the AMC's operations, as it may rank as an unsecured creditor in the event of a broker's insolvency. The AMC is not limited by a specific portfolio turnover rate, which may result in high turnover due to various factors, such as seeking better investment opportunities. A higher turnover leads to increased brokerage commissions and fees, which the AMC will bear directly. The AMC's investments also face liquidity and settlement risks, with limited withdrawal rights and no secondary market for interests. Investments may be illiquid, subject to legal restrictions, or lack a liquid market, leading to potential volatility and difficulty in selling at perceived fair value. The AMC may invest in event-driven situations, such as mergers or bankruptcies, where indiscriminate selling may undervalue assets. The Investment Manager may also pursue arbitrage opportunities during corporate events, aiming to capitalize on discounts relative to deal prices. Such event-driven investments are intended as a tactical strategy rather than a regular part of the AMC's operations.
Calculation Agent	Bank Frick AG, Landstrasse 14, 9496 Balzers, Liechtenstein Bank Frick has been family-owned since its founding as a licensed full-service bank in 1998 and operates with an entrepreneurial approach. Today, the bank is 100% controlled by the Kuno Frick Family Foundation (KFS). Bank Frick specializes in

	banking for professional clients, offering a fully integrated range of classic and blockchain banking services. In the field of regulated blockchain banking, Bank Frick is a European pioneer, providing services such as the trading and custody of crypto-assets as well as token sales. Their classic banking offerings encompass services in the capital markets sector, as well as services for funds and issuances with a focus on the design of European (AIF, UCITS), and national fund solutions. Additional information about the custodian bank (e.g., annual reports, brochures, etc.) can be obtained directly at their headquarters or online on their website at www.bankfrick.li .
Index Calculation Agent:	Not applicable
Administrator	Vistra Fund Services Limited, 4th Floor, St Paul's Gate, 22-24 New St, St Helier, Jersey JE1 4TR, Jersey
Custodian / Broker	General custodian: TradeStation Securities Inc., 8050 Southwest 10th Street, Suite 2000, Plantation, FL 33324, USA Additional Custodian: Bank Frick AG, Landstrasse 14, 9496 Balzers, Liechtenstein
Paying Agent	Bank Frick AG, Landstrasse 14, 9496 Balzers, Liechtenstein
Security Agent	Vistra (UK) Limited, 7th Floor 50 Broadway, London, United Kingdom, SW1H 0DB
Index Calculation Agent	Not applicable
Investment Manager	Dr. Blumer & Partner Asset Management AG, Landstrasse 8, 9496 Balzers, Liechtenstein
Investment Strategy	Objective General Investment Objective: The investment objective of the AMC is to achieve absolute return whilst considering relative capital protection through methodical risk management. The AMC intends to achieve this by applying the proprietary trading strategies blend, approaches and management, developed by the Investment Manager. Investment Strategies and Policies: The main strategies are based on but are not limited to distinctive price patterns setups, reversal settings, breakout settings, markets interaction/arbitrage patterns setups, variations and blends thereof, and more. The strategies trading signals are generated automatically through one or more proprietary and supervised trading programs and executed manually and/or automatically. The strategies usually engage in predefined long and short trades. The AMC engages leverage (implied or explicit) as needed according to the strategies in place and their relative and current marketplace conditions and definitions. The leverage level might fluctuate considerably depending of the various allocations and model variations. As such it is also possible that in some periods not all or none of the capital is engaged or allocated. Investment Restrictions: None. Leverage Policy The AMC will invest through accounts that allow intraday and overnight leveraged trading allocations and as such will engage in leveraged (implied or explicit) transactions as the Investment Manager shall determine. Strategic Asset Allocation

	Underlying Assets: The strategies apply to the S&P500 Future, the Nasdaq100 Future and the Gold Future. As such, the strategies could also extend to derivatives of these, such as Options, ETFs, ETNs and more. Strategies could further be extended to other main Market Indexes, in the USA and/or Internationally, and/or main Commodities. Diversification: Is proprietarily strategically applied among the different underlying in the AMC. Risk Management: Is proprietarily strategically applied to the AMC. Unless otherwise determined or necessary, positions are entered with a pre-defined position target and risk management in place.
Market Maker	Not applicable
Exchange	Not applicable
Significant or material change statement	There has been no significant change in the financial or trading position of the Issuer and there has been no material adverse change in the financial position or the prospects of the Issuer since 20.12.2023
Responsibility	The Issuer has taken all reasonable care to ensure that the facts stated herein are true and accurate in all material respects, and that there are no other facts the omission of which would make misleading any statement in these Final Terms. Accordingly, the Issuer accepts responsibility for the information contained in these Final Terms.
Date of Board of Directors approval of issuance	3 January 2025

Signed on behalf of the Issuer as duly authorized representative:

By:  DocuSigned by: 0F8C8C66A11F460...  DocuSigned by: 4F5B570733C0476...

Alexandra
Nethercott-Parkes

Director

Marc Harris

Director

PART B – OTHER INFORMATION

Listing and admission to trading	Not applicable
Interests of natural and legal persons involved in the issue	So far as the Issuer is aware, no person involved in the offer of the Securities has an interest material to the offer
Third Party Information	Not applicable
Additional Selling Restrictions	Not applicable
Distribution / Authorized Offerors	An offer of the Securities may be made only by authorized offerors (the Authorized Offerors) in or from any jurisdiction in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Issuer. Offers of the Securities are conditional upon their issue and, as between the Authorized Offeror and their customers, any further conditions as may be agreed between them. The following financial intermediary/ies qualifies as an Authorized Offeror and shall be authorized to use the Base Prospectus, as completed by these Final Terms: Securities firms and banks that are able to settle creations and / or redemptions directly or indirectly through SIX SIS AG with the Paying Agent
Security Codes	Valoren: 139357980 ISIN: CH1393579805
Clearing Systems	SIX SIS AG
Terms and Conditions of the Offer	Securities are made available by the Issuer for subscription only to the Eligible Investors
Offer Period	Until end of validity of the Base Prospectus
Offer Price	Offer Price is the applicable value calculated in accordance with the calculation methodology applicable to the calculation of the Redemption Amount.
Conditions to which the offer is subject	Offers of the Products are conditional upon their issue and, as between the Authorised Offeror(s) and their customers, any further conditions as may be agreed between them. An Investor intending to acquire any Products is asked to consult his security house or bank whether the Products can be made available.
Details of the minimum and/or maximum amount of application	Not applicable
Details of the method and time limited for paying up and delivery the Securities	Not applicable
Manner in and date on which results of the offer are made available to the public	Not applicable
Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not applicable
Whether tranche(s) have been reserved for certain countries	Not applicable

Process for notification to applicants of the amount allotted and the indication whether dealing may begin before notification is made	Not applicable
Name(s) and address(es), to the extent known to the Issuer, of the places in the various countries where the offer takes place	EU / EEA / Switzerland
Name and address of financial intermediary/ies authorized to use the Base Prospectus, as completed by these Final Terms (the Authorized Offerors)	Securities firms and banks that are able to settle creations and / or redemptions directly or indirectly through SIX SIS AG with the Paying Agent

ISSUE-SPECIFIC SUMMARY

A. Introduction and Warnings

10C PCC (the “PCC”) with its registered office at 4th Floor, St Paul’s Gate, 22-24 New Street, St Helier, Jersey JE1 4TR, cs.je@vistra.com, phone +44 1534 504 700, with registration number 149624 and LEI **2138005684QJK2QTKX27** issues structured notes including actively managed certificates which may or may not be exchange traded under the Structured Notes and Certificates Program (the “**Program**”) on the basis of a Base Prospectus dated 20.12.2023 in conjunction with Final Terms specific to the issue of each Product.

This Base Prospectus was approved by the Finanzmarktaufsicht Liechtenstein, Landstrasse 109, Postfach 279, 9490 Vaduz (info@fma-li.li) on 19.12.2025 (prolongation of initial Base Prospectus dated 20.12.2023). These Final Terms relating to **OPTIROI AMC CHF** have initially been filed with the FMA on 13.01.2025 and re-filed on 19.12.2025 and will, together with the Base Prospectus, be made available at the registered office of the Paying Agent at <https://www.bankfrick.li/en/services/fund-and-capital-markets/capital-markets>

This overview contains a description of the main features and risks relating to the Issuer, the securities offered under the Program and the counterparties. The summary should always be read together with the Base Prospectus (as supplemented) and the Final Terms for a specific Product. A thorough examination of the full Base Prospectus and the Final Terms is therefore recommended prior to any decision to purchase or subscribe to Products issued under the Program. Investors have to consider that they are about to invest in financial products which are complex and not easy to understand, and which bear the risk that Investors may lose all or part of the invested capital. The Issuer points out that in the event that claims are brought before a court based on the information contained in the Base Prospectus, the Final Terms or this summary the plaintiff investor may, under national law of the member states of the European Economic Area (EEA), have to bear the costs of translating the Base Prospectus and the Final Terms prior to the commencement of proceedings. In addition, the Issuer points out that the **Issuer 10C PCC acting on behalf of 10C Cell 13 PC** who has tabled the summary including any translation thereof may be held liable in the event that the summary is misleading, inaccurate or inconsistent when read together with the Base Prospectus or the Final Terms or where it does not provide, when read together with the Base Prospectus or the Final Terms, key information in order to aid investors when considering whether to invest in the securities.

B. Key Information on the Issuer

1. Who is the Issuer of the Securities?

The issuer of the Products is **10C PCC acting on behalf of 10C Cell 13 PC**. The PCC is a protected cell company under the Jersey Companies Law and was incorporated and registered in Jersey on 10 July 2023 for an unlimited duration with Jersey registration number 149624. The registered office of the Issuer is, 4th Floor, St Paul’s Gate, 22-24 New Street, St Helier, Jersey JE1 4TR.

The Issuer has been established as a special purpose vehicle for the purpose of issuing structured products, each time acting on behalf of one of its protected cells, and certificates linked to certain Underlying, which typically will be collateralized. The products will not be listed on exchanges or trading venues in Switzerland or the EEA.

The sole shareholder of the PCC is Vistra Fund Services Limited in its capacity as trustee (in such capacity, the Jersey Trustee) of The Pine9 Purpose Trust (the Trust). The directors of the PCC are: Marc Walter Harris, Jersey, and Alexandra Nethercott-Parkes, Jersey.

The auditors of the Issuer are, until 31.12.2025, Grant Thornton AG, 9494 Schaan, Principality of Liechtenstein, from 01.01.2026 onwards, Grant Thornton AG, Kensington Chambers, 46/50 Kensington Place, St. Helier, Jersey JE1 1ET will be the auditors of the Issuer. The financial statements of the Issuer will be established in accordance with IFRS accounting standards for the first time for the business year ending on 31 December 2023 and are available at <https://www.bankfrick.li/en/document-download>.

2. What is the key financial information regarding the Issuer?

The financial year of the Issuer ends on 31 December of each year. The Issuer was incorporated on 10 July 2023, audited financial statements were prepared for the first time as of 31 December 2023 and can, together with the financial statements as of 31 December 2024, be reviewed and downloaded at <https://www.bankfrick.li/en/document-download>.

Income Statement	2024	2023
Profit / Loss and other comprehensive income of the year	-	-
Balance Sheet		
Net Financial Debt (Long term Debt plus Short Term Debt minus Cash)	6'630	-
Current Ratio (Current Assets / Current Liabilities)	1.000	-
Debt Equity Ratio (Total Liabilities /Total Shareholder Equity)	6630	-
Interest Coverage Ratio (Operating Income / Interest Expense)	0	-
Cash Flow Statement		
Net Cash Flows from Operating Activities	0	-
Net Cash Flows from Investment Activities	0	-
Net Cash flows from Financing Activities	0	-

3. What are the key risks that are specific to the Issuer?

The Issuer is a Special Purpose Vehicle

The Issuer is not an operating company. The Issuer is a special purpose vehicle with the sole business of issuing structured products. The contracts which may be entered into by the Issuer and the payments of the Issuer and the parties thereunder are structured to have the capacity to provide the Issuer with funds to service payments due and payable in respect of the Products and on any redemption by the Issuer of the Products.

PCC Structure

The PCC has been constituted as a protected cell company under the Jersey Companies Law. Each Series of Notes issued by the PCC (as specified in the relevant Final Terms) is a Series of Notes issued by a protected cell of the PCC. A protected cell company is a multi-cellular company whose principal feature is that each protected cell has its own distinct assets which are not available to creditors of other protected cells of that company or the company as a whole. The relevant provisions of the Jersey Companies Law have not yet been tested in the courts of Jersey, the United Kingdom or elsewhere and jurisdictions other than Jersey may not be prepared to accept that creditors of a particular Issuer are prevented from gaining access to the assets attributed to other Issuers, or that creditors of the PCC (in its own capacity) do not have access to those assets specifically designated as cellular assets. In order to minimise this risk: (i) service providers to the PCC will generally be required to agree that their fees will be paid solely from the assets of the PCC in its own capacity; and (ii) the Terms and Conditions of each Series of Notes will provide that any liability to a holder will be satisfied only out of the assets of the Issuer (being a specified protected cell). However, a court could determine that such agreements are not enforceable.

If the courts in Jersey, the United Kingdom or elsewhere were not to recognise and give effect to the segregation of PCC's and each of its protected cells' assets and the agreements with service providers and investors referred to above, and the cellular assets of any protected cell were held to be available to meet the liabilities of the PCC or any other protected cell, this could have a material and adverse effect on that protected cell's financial condition and prospects and the value of any relevant Series of Notes.

This means that if the segregation of assets of the PCC or each of its protected cells were not to be recognised, investors in the Products issued by PCC acting on behalf of a particular protected cell may have a reduced ability to recover all or part of their initial investment in the Products as their claim will be in competition with the claims of any other creditor of the PCC and any other creditor of the PCC acting on behalf of each of its other protected cells from time to time.

Credit and Insolvency Risk

Each Investor bears the general risk that the financial situation of the Issuer could deteriorate. Unless specified otherwise, Investors are exposed to the credit risk of the Issuer of the Products. The Products constitute unsubordinated obligations of the Issuer and rank *pari passu* with each other and all other current and future unsubordinated obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital. Collateralization reduces the credit risk of the Issuer only to the extent that the proceeds from the liquidation of Collateral (less the costs of liquidation, including the fees and expenses of the Security Agent, and payout) meet the investors' claims. Investors bear the risks, among others, that the liquidation of the Collateral may result in insufficient liquidation proceeds or, in extreme circumstances, that the Collateral may lose its value entirely before liquidation can take place.

Competition

There are a number of other issuers for products similar to the Products, and other competitors may enter the market at any time. The effect of new or additional competition on the Products or their market prices cannot be predicted or quantified. There are several large institutions such as BlackRock iShares and Barclays iPath, which have issued similar products in the past based on other underlyings. These competitors have significantly greater financial and legal resources than the Issuer and there is no guarantee that the Issuer will be able to compete successfully, or at all, with such competitors. Moreover, increased competition may severely impact the profitability and creditworthiness of the Issuer.

Potential Conflicts of Interest

The Issuer may issue other derivative instruments relating to Underlying Components. The introduction of such competing products may affect the market value of the Products. The Issuer may also receive non-public information relating to the Underlying Components that the Issuer may not make available to Investors. The directors of the Issuer do not have any interest that conflicts with that of the Issuer.

C. Key Information on the Products

1. What are the main features of the securities?

The **OPTIROI AMC CHF** issued under the Program is a structured debt note in the form of an actively managed certificate linked to Underlying assets as specified in the Final Terms. Products issued under the Program may be linked to transferable securities (including units in investment undertakings), digital assets (including crypto currencies), components of Indices or other assets (the "Underlying") or a basket or combination of such Underlying which may or may not be hedged and may or may not have long or short exposures to the daily performance of a referenced index, all as set out in the detailed Final Terms applicable to the respective Product.

The Issuer will credit the Underlyings or Underlying Components of the Products specified in the Final Terms to a Collateral Account on the basis of a Collateral Agreement with the Security Agent for the benefit of Investors to secure the Issuer's payment obligations under the Base Prospectus and the Final Terms.

The price movement of any one Product and the movement of the aggregate value of the Underlying, which will be specified in the Final Terms, correlates 1:1, but the entitlement of the Investor will be reduced by administration fees, custody fees, index licensing fees, investment management fees and other fees as applicable due to providers of services in relation to the Products (Investor Fees) and as determined in the Final Terms. Such value may be further adjusted by tracking errors resulting from foreign currency hedging, if any.

The Products are limited-recourse obligations of the Issuer. The entitlement of investors in a Series of Notes issued by the Issuer acting on behalf of one of its protected cells (as specified in the Final Terms) will be limited to the assets attributable to such cell.

Subject to the Selling Restrictions, the Securities are freely transferable.

2. Rights attached to the securities

The Securities do not bear interest and do not have a fixed maturity date.

The Issuer can at any time decide to redeem the Products (Call Option).

Investors can demand redemption by the Issuer by directly approaching the Paying Agent. Redemption can be requested in a frequency respectively in intervals as defined in the Final Terms for each Product ("Investor Redemption Date") and will, except if stated otherwise in the Final Terms, be linked to the valuation frequency of a certain Product.

On each Investor Redemption Date (as specified in the Final Terms), an Investor holding Securities in any Product may, in case of investors other than Eligible Investors through the intermediation of an Eligible Investor, by giving a Redemption Order to the Paying Agent within the Redemption Notice Period, redeem the Securities held by such Investor.

Redemption Amount

The amount per Product payable by the Issuer upon redemption will be calculated by the Calculation Agent unless set out otherwise in the Final Terms in the Settlement Currency in accordance with the formula set out in the relevant Final Terms (the **Redemption Amount**). Settlement will occur in the form of a cash payment, investors are not entitled to demand redemption in kind.

The Products constitute unsubordinated obligations of the Issuer and rank pari passu with each other and all other current and future unsubordinated obligations of the Issuer. The insolvency of the Issuer may lead to a partial or total loss of the invested capital, regardless of the Collateral.

3. Ranking of the securities in the event of insolvency

The rights of the Investors are limited to the payment of Redemption Amounts from proceeds of the realization or enforcement of the Collateral held on a Collateral Account for the Issuer on behalf of the Cell having issued the respective Series of Notes of a Product. Rights of investors to receive payments out of such collateral proceeds will be subordinated to the payment of certain costs, fees, expenses and other amounts due in respect of the Program. In case of realization or enforcement of the Collateral, the proceeds will be applied in the applicable order of priority under which amounts due to Investors will be subordinated to certain costs, fees, expenses and other amounts including (without limitation) the costs of liquidating the Collateral but will be senior to claims of other creditors of the Issuer.

4. Where will the securities be traded?

Products offered under this Program will not be listed or exchange traded.

5. What are the key risks that are specific to the securities?

Underlying assets

The value of Products is affected by the price and development of the Underlying or Underlying Components. The amount to be paid by the Issuer upon redemption of any Products, or, in respect of redemption, the amount of Collateral able to be redeemed, depends on the performance of these assets, as calculated in accordance with the Terms and Conditions. The Products are not capital protected at all and there is, therefore, a risk of partial or complete loss of investment.

In case of a Product referencing a basket of Underlying, the negative performance of a single component may outweigh a positive performance of other components and may have a negative impact on the return on the Products.

Liquidity

The Products will not be listed on an exchange or trading venue. Investors will therefore not be able to sell their Products except on a bilateral basis (OTC) and there is no noted market price for the products.

Execution Risk

It may be impossible to execute trades in any Underlying at the price quoted or such Underlying. Any discrepancies between the quoted price and the execution price may be the result of the availability of assets, any relevant spreads or fees at the exchange or discrepancies in the pricing across exchanges. The Issuer will take all reasonable steps to ensure optimal execution, but is limited by KYC requirements, custodianship solutions and availability of exchanges. The Issuer cannot, therefore, guarantee that the price at which any trade is executed is the best available price globally.

Realization of Collateral

If the amounts received upon the realization of Collateral are not sufficient to fully cover the fees and expenses of the Program and the parties involved and the Issuer's payment obligations to Investors, then Investors may incur a loss, which may be significant.

D. Key information on the offer of the notes to the public

1. Under which conditions and timetable can I invest in this security?

The **OPTIROI AMC CHF** shall be subject to a continual issuance and redemption mechanism, under which additional Securities of such Product may be issued, and Securities may be redeemed by Investors in accordance with the Terms and Conditions.

The Issuer will accept direct subscriptions only from regulated banks or brokers domiciled in the EU / EEA, Switzerland or the United Kingdom which are entitled to directly trade through SIX SIS AG and who meet the definition of a Professional Investor under the SPB Order ("**Eligible Investors**"). Other investors may purchase Securities by directly approaching their bank or broker (provided it is or has access to an Eligible Investor) or on the secondary market over the counter (OTC).

The Issuer can at any time decide to redeem the Products (Call Option). Eligible Investors can demand redemption by the Issuer by directly approaching the Paying Agent. Redemption can be requested in a frequency respectively in intervals as defined in the Final Terms for each Product and will, except if stated otherwise in the Final Terms, typically be linked to the valuation frequency of a certain Product.

Settlement

Settlement and Clearing of trades in the Securities takes place through SIX SIS AG or any other clearing system defined in the Final Terms.

Expenses

The costs of the issue of Products under the Program will be borne by the Issuer and will not be deducted from the issue proceeds.

Investors will be charged administration fees, custody fees, index licensing fees, investment management fees, performance fees and other fees due to providers of services in relation to the Products (Investor Fees) as further specified in the relevant Final Terms.

2. Why is this Prospectus being produced?

10C PCC was set up to issue structured products, acting in respect of its protected cells, including actively managed certificates linked to certain Underlying. 10C PCC has established the Structured Notes and Certificates Program (the Program), described in this Base Prospectus, under which Products may be issued from time to time.

The proceeds of the issue of a Series of Notes will, after deduction of costs and assets required for general corporate purposes, be invested in specific Underlying which will serve as Collateral for the obligations of the Issuer under this Base Prospectus.

Net proceeds the Issuer expects to generate through the issue of Products under the Program as well as estimated costs to accrue per Product, if any, will be specified in the Final Terms and Issue Specific Summary for each Product.

Potential Conflicts of Interest

Several participants to the transactions described in the Base Prospectus and these Final Terms are identical or do have close links. The Custodian at the same time acts as Paying Agent and Calculation Agent under the Program.

Appropriate procedures have been implemented to avoid any conflicts of interests adversely affecting the interests of Investors. Fees payable to all parties as well as independent parties, are disclosed in the Base Prospectus or the Final Terms.

EMISSIONSSPEZIFISCHE ZUSAMMENFASSUNG

A. Einleitung und Warnungen

10C PCC (die «PCC») mit Sitz in 4th Floor, St Paul's Gate, 22-24 New Street, St Helier, Jersey JE1 4TR, cs.je@vistra.com, Telefon +44 1534 504 700, mit der Handelsregisternummer 149624 und LEI **2138005684QJK2QTKX27** emittiert strukturierte Anleihen, einschliesslich aktiv verwalteter Zertifikate, die im Rahmen des Programms für strukturierte Anleihen und Zertifikate (das «**Programm**») auf der Grundlage des Basisprospekts vom 20.12.2023 in Verbindung mit den Final Terms, die für die Emission der einzelnen Produkte gelten, börsengehandelt sein können oder nicht.

Der Basisprospekt wurde von der Finanzmarktaufsicht Liechtenstein, Landstrasse 109, Postfach 279, 9490 Vaduz (info@fma-li.li) am 19.12.2025 («Verlängerung» des initialen Basisprospekts vom 20.12.2023) genehmigt. Die vorliegenden Endgültigen Bedingungen beziehen sich auf die **OPTIROI AMC CHF** und wurden erstmals am 13.01.2025 sowie am 19.12.2025 bei der FMA hinterlegt. Die Endgültigen Bedingungen werden zusammen mit dem Basisprospekt am Sitz der Zahlstelle unter <https://www.bankfrick.li/de/services/fund-and-capital-markets/capital-markets> zur Verfügung gestellt.

Diese Zusammenfassung enthält eine Beschreibung der wichtigsten Merkmale und Risiken in Bezug auf die Emittentin, die im Rahmen des Programms angebotenen Wertpapiere und die Gegenparteien. Die Zusammenfassung ist immer zusammen mit dem Basisprospekt (in der ergänzten Fassung) und den Final Terms zu lesen. Es wird empfohlen, den vollständigen Basisprospekt und die Final Terms vor einer Entscheidung über den Kauf oder die Zeichnung von im Rahmen des Programms emittierten Produkten gründlich zu lesen. Anleger*innen sollten bedenken, dass sie im Begriff sind, in Finanzprodukte zu investieren, die komplex und nicht einfach zu verstehen sind und die das Risiko bergen, dass sie ihr investiertes Kapital ganz oder teilweise verlieren können. Die Emittentin weist darauf hin, dass für den Fall, dass aufgrund der im Basisprospekt, den Final Terms oder dieser Zusammenfassung enthaltenen Informationen vor einem Gericht Ansprüche geltend gemacht werden, der klagende Anleger oder die klagende Anlegerin nach nationalem Recht der Mitgliedstaaten des Europäischen Wirtschaftsraums (EWR) möglicherweise die Kosten für die Übersetzung des Basisprospekts und der Final Terms vor Prozessbeginn zu tragen hat. Darüber hinaus weist die Emittentin darauf hin, dass die **Emittentin 10C PCC, die im Namen von 10C Cell 13 PC handelt** und die Zusammenfassung einschliesslich einer Übersetzung davon vorgelegt hat, haftbar gemacht werden kann, wenn die Zusammenfassung irreführend, unrichtig oder widersprüchlich ist, wenn sie zusammen mit dem Basisprospekt oder den Final Terms gelesen wird oder wenn sie in Verbindung mit dem Basisprospekt oder den Final Terms wesentliche Informationen, die Anleger*innen bei der Entscheidung über eine Anlage in die Wertpapiere helfen, nicht enthält.

B. Wesentliche Informationen über die Emittentin

1. Wer ist die Emittentin der Wertpapiere?

Die Emittentin der Produkte ist **10C PCC, die im Namen von 10C Cell 13 PC handelt**. Die PCC ist eine Protected Cell Company nach dem Jersey Companies Law und wurde am 10. Juli 2023 in Jersey für eine unbefristete Dauer mit der Jersey-Handelsregisternummer 149624 gegründet und eingetragen. Der eingetragene Sitz der Emittentin ist 4th Floor, St Paul's Gate, 22-24 New Street, St Helier, Jersey JE1 4TR.

Die Emittentin wurde als Special Purpose Vehicle gegründet, um strukturierte Produkte sowie Zertifikate, zu emittieren, die an bestimmte Basiswerte gebunden sind und die in der Regel abgesichert werden. Die Emittentin handelt jeweils im Namen einer ihrer Protected Cells. Die Produkte werden nicht an Börsen oder Handelsplätzen in der Schweiz oder dem EWR notiert.

Alleiniger Aktionär der PCC ist Vistra Fund Services Limited in seiner Eigenschaft als Treuhänder (in dieser Eigenschaft der Jersey Trustee) des Pine9 Purpose Trust (der Trust). Die Direktoren der PCC sind: Marc Walter Harris, Jersey, und Alexandra Nethercott-Parkes, Jersey.

Die Revisionsstelle der Emittentin ist, bis zum 31.12.2025, die Grant Thornton AG, 9494 Schaan, Fürstentum Liechtenstein. Ab dem 01.01.2026 ist die Revisionsstelle der Emittentin die Grant Thornton AG, Kensington Chambers, 46/50 Kensington Place, St. Helier, Jersey JE1 1ET. Die Jahresrechnung der Emittentin wird erstmals für das am 31. Dezember 2023 endende Geschäftsjahr nach den IFRS-Rechnungslegungsstandards erstellt und ist abrufbar über <https://www.bankfrick.li/en/document-download>

2. Wie lauten die wichtigsten Finanzinformationen über die Emittentin?

Das Geschäftsjahr der Emittentin endet am 31. Dezember eines jeden Jahres. Die Emittentin wurde am 10. Juli 2023 gegründet, geprüfte Jahresabschlüsse werden erstmals per 31. Dezember 2023 bereitgestellt und sind gemeinsam mit dem Jahresabschluss per 31.12.2024 unter <https://www.bankfrick.li/en/document-download> abrufbar.

Erfolgsrechnung	2024	2023
Gewinn / Verlust und sonstiges Gesamtergebnis des Jahres	-	-
Bilanz		
Nettoverschuldung (Langfristige Schulden plus kurzfristige Schulden minus liquide Mittel)	6'630	-
Current Ratio (Umlaufvermögen / kurzfristige Verbindlichkeiten)	1.000	-
Verschuldungsgrad (Gesamtverbindlichkeiten / Eigenkapital)	6630	-
Zinsdeckungsgrad (Operatives Ergebnis / Zinsaufwand)	0	-
Geldflussrechnung		
Netto-Cashflow aus operativer Tätigkeit	0	-
Netto-Cashflow aus Investitionstätigkeit	0	-
Netto-Cashflow aus Finanzierungstätigkeit	0	-

3. Welches sind die Hauptrisiken der Emittentin?

Die Emittentin ist ein Special Purpose Vehicle.

Die Emittentin ist keine operativ tätige Gesellschaft. Die Emittentin ist ein Special Purpose Vehicle, dessen einziger Geschäftszweck die Emission von strukturierten Produkten ist. Die Verträge, die von der Emittentin abgeschlossen werden können, sowie die Zahlungen der Emittentin und der Vertragsparteien sind so strukturiert, dass der Emittentin ausreichend Mittel zufließen um die fälligen Zahlungen in Bezug auf die Produkte sowie im Falle von Rücknahmen der Produkte durch die Emittentin zu begleichen.

PCC-Struktur

Die PCC wurde als eine Protected Cell Company nach dem Jersey Companies Law gegründet. Jede von der PCC begebene Serie von Anleihen (wie in den jeweiligen Final Terms angegeben) wird von einer Protected Cell der PCC emittiert. Eine Protected Cell Company ist ein mehrzelliges Unternehmen, dessen Hauptmerkmal darin besteht, dass jede Protected Cell über eigene Vermögenswerte verfügt, die den Gläubiger*innen anderer Protected Cells dieses Unternehmens oder des Unternehmens als Ganzes nicht zur Verfügung stehen. Die einschlägigen Bestimmungen des Jersey Companies Law wurden noch nicht vor den Gerichten Jerseys, des Vereinigten Königreichs oder anderswo erprobt, und andere Jurisdiktionen als Jersey sind möglicherweise nicht bereit anzuerkennen, dass Gläubiger einer bestimmten Emittentin keinen Zugang zu Vermögenswerten erhalten, die anderen Emittenten zugerechnet werden, oder dass Gläubiger*innen der PCC (in ihrer Eigenschaft als solche) keinen Zugang zu den Vermögenswerten haben, die als Vermögenswerte einer bestimmten Zelle ausgewiesen sind. Um dieses Risiko zu minimieren: (i) müssen alle Dienstleister der PCC zustimmen, dass ihre Gebühren ausschliesslich aus den Vermögenswerten der PCC selbst gezahlt werden; und (ii) sehen die Bedingungen jeder Serie von Anleihen vor, dass jegliche Haftung gegenüber einem Inhaber nur aus den Vermögenswerten der Emittentin (einer bestimmten Protected Cell) erfüllt werden. Ein Gericht könnte jedoch entscheiden, dass solche Vereinbarungen nicht vollstreckbar sind.

Sollten die Gerichte in Jersey, im Vereinigten Königreich oder anderswo die Trennung der Vermögenswerte der PCC und jeder ihrer Protected Cells sowie die oben genannten Vereinbarungen mit Dienstleistern und Anleger*innen nicht anerkennen und durchsetzen und die Vermögenswerte einer Protected Cell als verfügbar erachtet werden, um die Verbindlichkeiten der PCC oder einer anderen Protected Cell zu erfüllen, könnte dies wesentliche und nachteilige Auswirkungen auf die finanzielle Lage und die Aussichten dieser Protected Cell sowie den Wert der betreffenden Serie von Anleihen haben.

Dies bedeutet, dass Anleger*innen, die in die von der PCC im Namen einer bestimmten Protected Cell emittierten Produkte investieren, bei einer Nichtanerkennung der Vermögenstrennung der PCC oder der einzelnen Protected Cells möglicherweise nicht oder nur zum Teil in der Lage sein könnten, ihre ursprüngliche Investition in die Produkte ganz oder teilweise zurückzuerhalten, da ihre Forderung mit den Forderungen aller anderen Gläubiger*innen der PCC sowie aller anderen Gläubiger*innen anderer Zellen in Konkurrenz steht.

Kredit- und Zahlungsunfähigkeitsrisiken

Sämtliche Anleger*innen tragen das allgemeine Risiko, dass sich die finanzielle Situation der Emittentin verschlechtern könnte. Sofern nicht anders angegeben, sind die Anleger*innen dem Kreditrisiko des Emittenten der Produkte ausgesetzt. Die Produkte stellen nicht nachrangige Verbindlichkeiten der Emittentin dar und sind untereinander sowie mit allen anderen gegenwärtigen und zukünftigen nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig. Die Zahlungsunfähigkeit der Emittentin kann zu einem teilweisen oder vollständigen Verlust des investierten Kapitals führen. Die Absicherung reduziert das Kreditrisiko der Emittentin nur in dem Masse, in dem die Erlöse aus der Verwertung der Sicherheiten (abzüglich der Kosten der Verwertung, einschliesslich der Gebühren und Auslagen des Security Agent, und der Auszahlung) die Ansprüche der Anleger*innen erfüllen. Anleger*innen tragen unter anderem das Risiko, dass die Liquidation der Sicherheiten zu unzureichenden Liquidationserlösen führt oder dass die Sicherheiten im Extremfall ihren Wert vollständig verlieren, bevor die Liquidation überhaupt stattfinden kann.

Wettbewerb

Es gibt eine Reihe anderer Emittenten von Produkten, die den Produkten ähnlich sind. Zudem können jederzeit weitere Wettbewerber in den Markt eintreten. Die Auswirkungen eines neuen oder zusätzlichen Wettbewerbs auf die Produkte oder ihre Marktpreise lassen sich weder vorhersagen noch quantifizieren. Es gibt mehrere grosse Institute wie BlackRock iShares und Barclays iPath, die in der Vergangenheit ähnliche Produkte auf der Grundlage anderer Basiswerte emittiert haben. Diese Konkurrenten verfügen über wesentlich grössere finanzielle und rechtliche Ressourcen als die Emittentin, und es gibt keine Garantie dafür, dass die Emittentin in der Lage sein wird, mit diesen Konkurrenten erfolgreich oder überhaupt zu konkurrieren. Darüber hinaus kann ein verstärkter Wettbewerb die Rentabilität und Kreditwürdigkeit der Emittentin erheblich beeinträchtigen.

Potenzielle Interessenkonflikte

Die Emittentin kann weitere derivative Instrumente emittieren, die sich auf Basiswertkomponenten beziehen. Die Einführung solcher konkurrierender Produkte kann den Marktwert der Produkte beeinträchtigen. Die Emittentin kann auch nicht-öffentliche Informationen, die sich auf die Basiswertkomponenten beziehen, erhalten, welche die Emittentin den Anleger*innen nicht zugänglich machen darf. Die Direktoren der Emittentin haben keine Interessen, die mit den Interessen der Emittentin in Konflikt stehen.

C. Wesentliche Informationen in Bezug auf die Produkte

1. Was sind die wichtigsten Merkmale der Wertpapiere?

Bei den im Rahmen des Programms emittierten **OPTIROI AMC CHF** handelt es sich um strukturierte Schuldverschreibungen in der Form von aktiv verwalteten Zertifikaten, die an die in den Final Terms genannten zugrunde liegenden Vermögenswerte gebunden sind. Die im Rahmen des Programms emittierten Produkte können übertragbare Wertpapiere (einschliesslich Anteilen an Investmentunternehmen), digitale Vermögenswerte (einschliesslich Kryptowährungen), Komponenten von Indizes oder andere Vermögenswerte (der «Basiswert») oder einen Korb bzw. eine Kombination solcher Basiswerte gebunden sein, die abgesichert oder nicht abgesichert sein und sowohl langfristige als auch kurzfristige Risiken in Bezug auf die tägliche Wertentwicklung eines referenzierten Index aufweisen können, wie in den detaillierten Final Terms für das jeweilige Produkt dargelegt ist.

Die Emittentin wird die in den Final Terms genannten Basiswerte bzw. Basiswertkomponenten der Produkte auf der Grundlage einer Sicherheitenvereinbarung mit dem Security Agent zugunsten der Anleger*innen einem Sicherheitenkonto gutschreiben, um die Zahlungsverpflichtungen der Emittentin gemäss dem Basisprospekt und den Final Terms zu sichern.

Die Kursentwicklung eines Produkts und die Entwicklung des Gesamtwerts des in den Final Terms festgelegten Basiswerts korrelieren 1:1. Der Anspruch der Anleger*innen wird jedoch um Verwaltungs-, Depot-, Indexlizenz-, Anlageverwaltungs- und sonstige Gebühren, die den Anbieter*innen von Dienstleistungen im Zusammenhang mit den Produkten (Anlegergebühren) zustehen und in den Final Terms festgelegt werden, gekürzt. Dieser Wert

kann durch Tracking Errors, die sich aus einer eventuellen Fremdwährungsabsicherung ergeben, weiter angepasst werden.

Bei den Produkten handelt es sich um Verbindlichkeiten der Emittentin mit beschränktem Rückgriffsrecht. Der Anspruch von Investoren einer Serie von Anleihen, die von der Emittentin im Namen einer ihrer Protected Cells (wie in den Final Terms angegeben) emittiert wird, ist auf jene Vermögenswerte beschränkt, die dieser Cell zuzuordnen sind.

Vorbehaltlich der Selling Restrictions sind die Wertpapiere frei übertragbar.

2. Mit den Wertpapieren verbundene Rechte

Die Wertpapiere sind nicht verzinslich und haben kein festes Fälligkeitsdatum.

Die Emittentin kann jederzeit beschliessen, die Produkte zurückzukaufen (Call-Option).

Anleger*innen können die Rücknahme durch die Emittentin verlangen, indem sie sich direkt an die Zahlstelle wenden. Die Rücknahme kann in Intervallen beantragt werden, die in den Final Terms für jedes Produkt festgelegt sind («Rückzahlungsdatum für Anleger*innen»), und ist, sofern in den Final Terms nicht anders angegeben, an die Bewertungshäufigkeit eines bestimmten Produkts gebunden.

An jedem Rückzahlungsdatum für Anleger*innen (wie in den Final Terms angegeben) können Anleger*innen, die Wertpapiere halten - im Falle von Anleger*innen, die keine zugelassenen Anleger*innen sind, durch die Vermittlung von zugelassenen Anleger*innen - innerhalb der Rückzahlungsankündigungsfrist einen Rückzahlungsauftrag an die Zahlstelle übermitteln.

Rückzahlungsbetrag

Der von der Emittentin bei Rückzahlung zu zahlende Betrag pro Produkt wird vom Calculation Agent, sofern in den Final Terms nichts anderes bestimmt ist, in der Abrechnungswährung gemäss der in den jeweiligen Final Terms dargelegten Formel berechnet (der **Rückzahlungsbetrag**). Die Abrechnung erfolgt in Form einer Barzahlung. Die Anleger*innen sind nicht berechtigt, eine Rückzahlung in Form von Sachleistungen zu verlangen.

Die Produkte stellen nicht nachrangige Verbindlichkeiten der Emittentin dar und sind untereinander und mit allen anderen gegenwärtigen und zukünftigen nicht nachrangigen Verbindlichkeiten der Emittentin gleichrangig. Die Zahlungsunfähigkeit der Emittentin kann ungeachtet allfälliger Sicherheiten zu einem teilweisen oder vollständigen Verlust des investierten Kapitals führen.

3. Rangfolge der Wertpapiere im Falle der Insolvenz

Die Rechte der Anleger*innen sind auf die Zahlung von Rückzahlungsbeträgen aus den Erlösen der Verwertung oder Vollstreckung jener Sicherheiten beschränkt, die auf einem Sicherheitenkonto für die Emittentin im Auftrag jener Cell, welche die jeweilige Serie von Anleihen eines Produkts emittiert hat, gehalten werden. Die Rechte der Anleger*innen auf Zahlungen aus diesen Erlösen sind gegenüber Ansprüchen auf Bezahlung bestimmter Kosten, Gebühren, Ausgaben und sonstiger im Zusammenhang mit dem Programm fälliger Beträge nachrangig. Im Falle einer Verwertung oder Vollstreckung der Sicherheiten werden die Erlöse gemäss der anwendbaren Rangfolge so verwendet, dass die den Anleger*innen geschuldeten Beträge bestimmten Kosten, Gebühren, Aufwendungen und anderen Beträgen, einschliesslich (ohne Einschränkung) der Kosten für die Liquidation der Sicherheiten, nachgeordnet bezahlt werden die Ansprüche der Anleger aber gegenüber den Forderungen anderer Gläubiger*innen der Emittentin Vorrang haben.

4. Wo werden die Wertpapiere gehandelt werden?

Die im Rahmen dieses Programms angebotenen Produkte werden nicht börsennotiert oder börsengehandelt.

5. Welches sind die Hauptrisiken, die mit den Wertpapieren verbunden sind?

Zugrunde liegende Vermögenswerte

Der Wert der Produkte wird durch den Preis und die Entwicklung des Basiswerts oder der Basiswertkomponenten beeinflusst. Der von der Emittentin bei der Rückzahlung der Produkte zu zahlende Betrag bzw., im Falle von Rückzahlungen, der Erlös aus den für eine Verwertung zur Verfügung stehenden Sicherheiten, hängt von der Wertentwicklung dieser Vermögenswerte ab, wie gemäss den Emissionsbedingungen berechnet. Die Produkte sind nicht kapitalgeschützt und es besteht daher das Risiko eines teilweisen oder vollständigen Verlustes der Investition.

Bei einem Produkt, das sich auf einen Korb von Basiswerten bezieht, kann die negative Entwicklung einer einzelnen Komponente die positive Entwicklung anderer Komponenten überwiegen und sich negativ auf die Rendite der Produkte auswirken.

6. Liquidität

Die Produkte werden nicht an einer Börse oder einem Handelsplatz notiert sein. Investoren werden daher ihre Produkte nur auf bilateraler Basis (OTC) verkaufen können, wobei es keinen notierten Marktpreis für die Produkte gibt.

Durchführungsrisiko

Es besteht das Risiko, dass Geschäfte mit einem Basiswert nicht zu dem für diesen Basiswert angegebenen Preis durchgeführt werden können. Etwaige Abweichungen zwischen dem angegebenen Preis und dem Ausführungspreis können auf die Verfügbarkeit von Vermögenswerten, etwaige relevante Spreads oder Gebühren an der Börse oder Diskrepanzen in der Preisbildung an verschiedenen Börsen zurückzuführen sein. Die Emittentin ergreift alle angemessenen Massnahmen, um eine optimale Ausführung zu gewährleisten, ist jedoch durch die KYC-Anforderungen, Verwahrungslösungen und die Verfügbarkeit von Börsenplätzen eingeschränkt. Die Emittentin kann daher nicht garantieren, dass der Preis, zu dem ein Handel ausgeführt wird, der beste weltweit verfügbare Preis ist.

Verwertung von Sicherheiten

Wenn die bei der Verwertung der Sicherheiten erhaltenen Beträge nicht ausreichen, um die Gebühren und Kosten des Programms und der beteiligten Parteien sowie die Zahlungsverpflichtungen der Emittentin gegenüber den Anleger*innen vollständig zu decken, können die Anleger*innen möglicherweise einen erheblichen Verlust erleiden.

D. Wesentliche Informationen über das öffentliche Angebot der Anleihen

1. Unter welchen Bedingungen und nach welchem Zeitplan kann ich in dieses Wertpapier investieren?

Für den **OPTIROI AMC CHF** besteht ein fortlaufender Emissions- und Rücknahmemechanismus, in dessen Rahmen zusätzliche Wertpapiere dieses Produkts emittiert und Wertpapiere von Anleger*innen gemäss den Emissionsbedingungen zurückgekauft werden können.

Die Emittentin akzeptiert Direktzeichnungen nur von regulierten Banken oder Brokern mit Sitz in der EU/dem EWR, der Schweiz oder dem Vereinigten Königreich, die berechtigt sind, direkt über SIX SIS AG zu handeln und welche die Definition einer professionellen Anlegerin oder eines professionellen Anlegers gemäss der SPB-Anordnung erfüllen («**zugelassene Anleger*innen**»). Andere Anleger*innen können die Wertpapiere direkt bei ihrer Bank oder ihrem Broker (sofern es sich um eine geeignete Anlegerin oder einen geeigneten Anleger handelt) oder auf dem Sekundärmarkt ausserbörslich (OTC) erwerben.

Die Emittentin kann jederzeit beschliessen, die Produkte zurückzukaufen (Call-Option). Zugelassene Anleger*innen können die Rücknahme durch die Emittentin verlangen, indem sie sich direkt an die Zahlstelle wenden. Die Rücknahme kann in einer Häufigkeit bzw. in Intervallen verlangt werden, die in den Final Terms für jedes Produkt festgelegt sind, und ist, sofern in den Final Terms nicht anders angegeben ist, in der Regel an die Bewertungshäufigkeit eines bestimmten Produkts gebunden.

Abrechnung

Die Abwicklung und Abrechnung von Geschäften mit den Wertpapieren erfolgt über die SIX SIS AG oder ein anderes in den Final Terms definiertes Clearing-System.

Kosten

Die Kosten für die Emission von Produkten im Rahmen des Programms werden von der Emittentin getragen und nicht vom Emissionserlös abgezogen.

Den Anleger*innen werden Verwaltungsgebühren, Depotgebühren, Indexlizenzgebühren, Anlageverwaltungsgebühren, Performancegebühren und andere Gebühren, die den Anbieter*innen von Dienstleistungen im Zusammenhang mit den Produkten zustehen (Anlegergebühren), in Rechnung gestellt, wie in den jeweiligen Final Terms näher beschrieben.

2. Warum wird dieses Prospekt erstellt?

10C PCC wurde gegründet, um, jeweils handelnd in Bezug auf ihre Protected Cells, strukturierte Produkte einschliesslich aktiv verwalteter Zertifikate zu emittieren, die, an bestimmte Basiswerte gebunden sind. 10C

PCC hat das in diesem Basisprospekt beschriebene Programm für strukturierte Anleihen und Zertifikate (das Programm) eingerichtet, unter dem von Zeit zu Zeit Produkte emittiert werden können.

Die Erlöse aus der Emission einer Serie von Anleihen werden nach Abzug von Kosten und Vermögenswerten, die für allgemeine Unternehmenszwecke benötigt werden, in bestimmte Basiswerte investiert, die als Sicherheiten für die Verpflichtungen der Emittentin aus diesem Basisprospekt dienen.

Die Nettoerlöse, welche die Emittentin durch die Emission von Produkten im Rahmen des Programms zu erzielen erwartet, sowie die geschätzten Kosten, die pro Produkt anfallen, werden in den Final Terms und der emissionspezifischen Zusammenfassung für jedes Produkt angegeben.

Potenzielle Interessenkonflikte

Mehrere Teilnehmer*innen an den im Basisprospekt und in diesen Final Terms beschriebenen Transaktionen sind identisch oder stehen in enger Verbindung zueinander. Die Verwahrstelle fungiert gleichzeitig als Paying Agent und Calculation Agent im Rahmen des Programms.

Es wurden geeignete Verfahren eingeführt, um Interessenskonflikte zu vermeiden, die sich nachteilig auf die Interessen der Anleger*innen auswirken. Die Gebühren, die an alle Parteien sowie an unabhängige Parteien zu zahlen sind, werden im Basisprospekt oder in den Final Terms offengelegt.